Business Context and Reporting Period
Company: Outlook Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 22, 2020
Reporting Period: Specific event date (June 22, 2020)
Context: The Company, an emerging growth company, announced the entry into material definitive agreements for a registered direct offering of common stock and a private placement with a significant stockholder to raise capital.
Key Financial Metrics and Transaction Details
| Transaction Component | Details | Financial Impact |
|---|---|---|
| Registered Direct Offering | 8,407,411 shares of Common Stock | $10.2 million gross proceeds |
| Offering Price | $1.215 per share | N/A |
| Syntone Private Placement | 823,045 shares of Common Stock | $1.0 million gross proceeds |
| Placement Agent Fees | 7.0% cash fee + 1.0% management fee + expenses | Expenses capped at $147,900 |
| Placement Agent Warrants | 588,519 shares (7.0% of offering) | Exercise price: $1.51875; 5-year term |
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels. It focuses solely on the capital raise transaction.
Material Changes and Transaction Structure
- Capital Raise: The Company is raising approximately $11.2 million in aggregate gross proceeds ($10.2 million from the registered direct offering and $1.0 million from the Syntone private placement).
- Share Issuance: A total of 9,230,456 shares of Common Stock are being issued across both transactions.
- Valuation: Both transactions were executed at a uniform purchase price of $1.215 per share.
- Regulatory Status: The Registered Direct Offering utilizes an effective shelf registration statement (Form S-3). The Syntone Private Placement is exempt under Section 4(a)(2) and Rule 506(b) of the Securities Act.
Outlook, Risks, and Management Commentary
- Closing Dates: The Registered Direct Offering is expected to close on or about June 24, 2020. The Syntone Private Placement is expected to close on or about July 21, 2020.
- Conditions: Both closings are subject to the satisfaction of customary closing conditions.
- Placement Agent: H.C. Wainwright & Co., LLC was engaged as the exclusive placement agent.
- Risks/Contingencies: The filing does not explicitly detail new operational risks but notes that the descriptions of agreements are qualified by reference to the full text of the exhibits.
Investor Verification Checklist
- Verify the final closing dates for both the Registered Direct Offering and the Syntone Private Placement.
- Confirm the exact net proceeds after deducting the 7.0% placement fee, 1.0% management fee, and the capped $147,900 in expenses.
- Review the full text of the Securities Purchase Agreements (Exhibits 10.1 and 10.2) for specific covenants or restrictions.
- Assess the dilution impact of issuing 9,230,456 new shares plus 588,519 placement agent warrants.
- Check subsequent filings for the actual cash received and any changes to the offering terms.